Sleeping giants: cardiac metastases from gastrointestinal neuroendocrine neoplasms

Chrissy Bolton,1 Kyriacos Mouyis,1 Themistoklis Liassides,2 Constantinos G Missouris1,2

DESCRIPTION

Neuroendocrine neoplasms affecting the heart are a rare but important condition to diagnose as they carry an adverse prognosis. We report an asymptomatic patient who presented with an incidental finding of a huge mass in the right side of the heart.

A previously fit man was investigated elsewhere for abnormal liver function tests with a liver biopsy, undertaken via the transjugular approach. During the procedure, severe tricuspid regurgitation was discovered. A transthoracic echocardiogram identified a 6×6×4 cm heterogeneous vascular mass infiltrating the right ventricular free wall and distorting the annulus of the tricuspid valve, obliterating the right ventricle (figure 1). The tricuspid valve leaflets were tethered and non-coapting causing free-flowing tricuspid regurgitation.

The treating physicians’ differential included a primary cardiac neoplasm (angiosarcoma), metastasis and cardiac lymphoma. A thoracic magnetic resonance scan, median sternotomy and open biopsy of the mass was undertaken to elucidate aetiology. Functional imaging could have helped distinguish between a primary and secondary neoplasm. Within days of the open biopsy, the patient deteriorated rapidly, experiencing profuse diarrhoea and exertional dyspnoea. Histopathology results were not available, and clinical suspicion of carcinoid syndrome was low; however, 5-hydroxyindoleacetic acid tests could have aided diagnosis. Colonoscopy did not identify any lesions.

Histopathology evaluation identified a well-differentiated (G1) neuroendocrine neoplasm, with a proliferation index under 1% and mitotic count of 0/10 high power fields. Immunostaining was positive for synaptophysin, chromogranin, serotonin and CDX-2 making spread from a gastro-intestinal primary likely. A contrast-enhanced CT scan looking for a primary neuroendocrine lesion identified an avidly enhancing 1.2 cm intraluminal lesion within the terminal ileum, with an adjacent calcified ileocolic nodal mass. The cardiac mass was now measured at 8×6×4.9 cm (figure 1). Three weeks following the biopsy, he presented to the emergency department with hypotension and a reduced level of consciousness. Despite supportive measures, he sadly died of cardiogenic shock.

Neuroendocrine neoplasms are epithelial neoplasms mostly arising from the gastro-entero-pancreatic system, with an incidence of around 2.5–5 per 100 000 persons.1 In serotonin-secreting neoplasms, carcinoid syndrome may develop as hepatic function becomes compromised. This is characterised by flushing, diarrhoea and bronchoconstriction. Cardiac metastases of neuroendocrine neoplasms have been reported up to 5 cm in diameter previously.1 Structural deformity contributed to tricuspid regurgitation in this case; however, cardiac valve changes may also occur as a result of elevated circulating neurohormones and vasoactive substances.2 Carcinoid heart disease arising from fibrosis and smooth muscle...
proliferation classically causes tricuspid valve regurgitation too.\(^2\)

This case demonstrates that neuroendocrine neoplasms originating from the midgut may present asymptotically, through detection of cardiac metastases. It highlights the significance of cardiac imaging modalities, median sternotomy and open biopsy in reaching a diagnosis.

**Learning points**

- Giant cardiac metastases can be the presenting symptom in neuroendocrine neoplasms that are otherwise asymptomatic.
- Open biopsy may be fundamental in acquiring a diagnosis but may pose a decompensation risk.
- Functional imaging may provide a valuable tool in characterising neuroendocrine tumours.

**Acknowledgements** We would like to thank the patient’s next of kin for assisting us in sharing this case.

**Contributors** Acquisition of data and manuscript writing: CB. Acquisition of data and manuscript review: KM. Interpretation of data and manuscript review: TL. Conception of case and manuscript review: CGM.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent** Next of kin consent obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**
